Cereno Scientific has expanded the development focus of its oral HDAC inhibitor CS014 to include pulmonary hypertension associated with interstitial lung disease (PH-ILD), a severe condition with very limited treatment options and high unmet medical need. Originally developed for idiopathic pulmonary fibrosis (IPF), CS014 targets shared disease mechanisms including vascular remodeling, fibrosis, thrombosis, and inflammation—making PH-ILD a natural and scientifically driven extension. Following a successful Phase I study confirming a favorable safety profile, Cereno Scientific is now preparing for a Phase II study planned to begin in Q1 2027.
Read more at this link on PR Newswire
See also our article on CS1 at this link